LYTENAVA
Live / Applied — Second extension granted (statement of use) (as of 14 Oct 2025)
What this means for you
Not registered yet, but its 14 Sept 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98180421
- Mark type
- Stylized text
- Filed
- 14 Sept 2023
- Published for opposition
- 03 Sept 2024
- Attorney of record
- Kelley B. Harrington
Goods and services
- Class 005 — Pharmaceuticals: Injectable pharmaceutical preparations for the treatment of retinal disease; pharmaceuticals, namely, ophthalmic drugs for the treatment of retinal disease
Owner
- Outlook Therapeutics, Inc., Iselin, NJ, US
- Outlook Therapeutics, Inc., Iselin, NJ, US
Prosecution history
- 15 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Oct 2025 — SOU EXTENSION 2 GRANTED
- 14 Oct 2025 — SOU EXTENSION 2 FILED
- 14 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Apr 2025 — SOU EXTENSION 1 GRANTED
- 10 Apr 2025 — SOU EXTENSION 1 FILED
- 10 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 19 Mar 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 19 Mar 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 19 Mar 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 19 Mar 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 29 Oct 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 03 Sept 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Sept 2024 — PUBLISHED FOR OPPOSITION